Thienopyridones as AMPK activators for the treatment of diabetes and obesity

US7119205B2 · kind B2 · utility

Assignee

• Abbott Laboratories · US

Inventors

• Rajesh Iyengar · Newton, US
• Andrew S. Judd · Grayslake, US
• Gang Zhao · Oceanside, US
• Philip R. Kym · Libertyville, US
• Hing L. Sham · South San Francisco, US
• Yugui Gu · Libertyville, US
• Gang Liu · Sugar Land, US
• Mei Liu · Fargo, US
• Hongyu Zhao · Libertyville, US
• Richard F. Clark · Mundelein, US
• Ernst Frevert · Deerfield, US
• Barbara Cool · Highland Park, US
• Tianyuan Zhang · Gurnee, US
• Robert Keyes · Pleasant Prairie, US
• Todd M. Hansen · Grayslake, US
• Zhili Xin · Lake Bluff, US

Key dates

• Filing date: May 17, 2004
• Grant date: Oct 10, 2006
• Expiry date: Sep 21, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.